| This week's sponsor is Premier Research. | | | A Brand New Day for Rare Cancer Study
As cancer's molecular origins emerge and researchers join forces, it's a new day for study of rare oncology. Read our white paper for patient viewpoints and trends in trial design, regulation, and legislation. Premier Research. It's what we do. Best. |
Top Stories Friday, December 16, 2016 In the week that Pfizer was rewarded for its $4.5 billion buyout of Anacor after the FDA approved its eczema med Eucrisa (crisaborole), rival Big Pharma Novartis wants to get in on the act as it announces a deal to buy Ziarco and its leading eczema candidate. Friday, December 16, 2016 Celgene's ongoing drive to diversify beyond cancer gathers pace with a five-year deal with Evotec to find new drugs for neurodegenerative diseases. Friday, December 16, 2016 A second patient has now been treated in the first trial of a stem cell therapy for Parkinson's disease developed by California biotech International Stem Cell Corporation (ISCO). Thursday, December 15, 2016 Scientists studying one family’s genetics to better understand congenital heart disease have discovered more than they bargained for. They found that the mutation that causes babies to be born with a hole in the heart also causes heart failure in adolescence. The findings have uncovered a potential new target for heart disease. Thursday, December 15, 2016 Three years ago, Pacific Biosciences stock leaped 73% on the news of a product development deal with Roche that saw the latter forking over $35 million up front. Now, the pair is calling it quits, freeing up PacBio to sell its tech in any market and Roche to focus on other projects. Thursday, December 15, 2016 Welcome to the latest edition of our weekly EuroBiotech Report. This week we saw the halo slip a little further from British investor Neil Woodford as he signalled a backing away from his investments in controversial biotech NW Bio after taking a bath on the company. BioInvent hit major trouble after having to can its leading phase 2 myeloma med a month after the FDA told it to stop dosing patients. And more. Friday, December 16, 2016 In this week's FiercePharmaAsia wrap-up, Japan will likely update its drug pricing reviews’ timetable, Pfizer is selling a plant in Pakistan, and Perrigo is also selling an API one in India. Thursday, December 8, 2016 FDA’s John Jenkins retires after 15 years leading the OND, Teva’s generics CEO Olafsson exits with Actavis’ transition still on the agenda, and Deborah Waterhouse will replace Dominique Limet as ViiV Healthcare's CEO. Plus more hirings, firings and retirings throughout the industry. | | | Ionis is in a $28 million payday from partner AstraZeneca for its new oncology med. Release Grünenthal has bagged a breakthrough tag from the FDA for its drug to help treat complex regional pain syndrome. Statement Europe's drug regulator has recommended seven meds this month, totaling 81 over the whole year. Release One of those recommended from the CHMP this month is Lilly's new oral arthritis treatment baricitinib. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Drug Development Boot CampTM 2017 November 15-16, 2017 | Boston, MA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA | 